sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Asthma and COPD Drugs Market by Disease (COPD and Asthma) by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics and Others) - Global Opportunity Analysis and Industry Forecasts, 2014-2022

Asthma and COPD Drugs Market by Disease (COPD and Asthma)...

Home / Categories / Healthcare
Asthma and COPD Drugs Market by Disease (COPD and Asthma) by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics and Others) - Global Opportunity Analysis and Industry Forecasts, 2014-2022
Asthma and COPD Drugs Market...
Report Code
RO1/113/1078

Publish Date
25/Nov/2024

Pages
120
PRICE
$ 5540/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 6654/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 9280/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
TABLE 1 ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 2 ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 3 COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4 ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS TYPE, 2014-2022 ($MILLION)
TABLE 5 COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6 LTA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 ICS DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 ANTICHOLINERGICS DRUG MARKET, BY GEOGRAPHY,
TABLE 9 2014-2022 ($MILLION)
TABLE 10 SABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 LABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 OTHER DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 14 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 15 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 16 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 17 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 18 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 19 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 20 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 21 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 22 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 23 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 24 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 25 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 26 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 27 BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 28 MERCK: COMPANY SNAPSHOT
TABLE 29 MERCK: OPERATING SEGMENTS
TABLE 30 GSK: COMPANY SNAPSHOT
TABLE 31 GSK: OPERATING SEGMENTS
TABLE 32 NOVARTIS: COMPANY SNAPSHOT
TABLE 33 NOVARTIS: OPERATING SEGMENTS
TABLE 34 ASTRAZENECA: COMPANY SNAPSHOT
TABLE 35 ASTRAZENECA: OPERATING SEGMENT
TABLE 36 ROCHE: COMPANY SNAPSHOT
TABLE 37 ROCHE: OPERATING SEGMENTS
TABLE 38 TEVA: COMPANY SNAPSHOT
TABLE 39 TEVA: OPERATING SEGMENTS
TABLE 40 VECTURA: COMPANY SNAPSHOT
TABLE 41 VECTURA: OPERATING SEGMENTS
TABLE 42 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 43 PFIZER: OPERATING SEGMENTS
TABLE 44 ABBOTT: COMPANY SNAPSHOT
TABLE 45 ABBOTT: OPERATING SEGMENTS
LIST OF FIGURE
FIG. 1 TOP INVESTMENT POCKETS IN GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
FIG. 3 PORTERS FIVE FORCES ANALYSIS OF GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 4 TOP IMPACTING FACTORS: GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2015 & 2022 (% SHARE)
FIG. 6 GLOBALASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 7 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 8 COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 9 COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 10 SERETIDE/ADVAIT MARKET, 2014-2022 ($MILLION)
FIG. 11 SYMBICORT MARKET, 2014-2022 ($MILLION)
FIG. 12 RELVAR/BREO ELLIPTA MARKET, 2014-2022 ($MILLION)
FIG. 13 FLUTIFORM MARKET, 2014-2022 ($MILLION)
FIG. 14 FLUTIFORM MARKET, 2014-2022 ($MILLION)
FIG. 15 SINGULAIR MARKET, 2014-2022 ($MILLION)
FIG. 16 QVAR MARKET, 2014-2022 ($MILLION)
FIG. 17 PULMICORT MARKET, 2014-2022 ($MILLION)
FIG. 18 AEROSPAN MARKET, 2014-2022 ($MILLION)
FIG. 19 FLOVENT MARKET, 2014-2022 ($MILLION)
FIG. 20 SPIRIVA MARKET, 2014-2022 ($MILLION)
FIG. 21 PROAIR MARKET, 2014-2022 ($MILLION)
FIG. 22 PROAIR MARKET, 2014-2022 ($MILLION)
FIG. 23 U.S.: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 24 CANADA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 25 MEXICO: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 26 GERMANY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 27 FRANCE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 28 UK: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 29 ITALY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 30 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 31 JAPAN: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 32 CHINA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 33 INDIA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 34 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 35 LATIN AMERICA: ASTHMA AND COPD DRUGSMARKET, 2014-2022 ($MILLION)
FIG. 36 MIDDLE EAST: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 37 AFRICA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 38 BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
FIG. 39 BOEHRINGER INGELHEIM: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 40 BOEHRINGER INGELHEIM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 41 MERCK: REVENUE, 2013-2015 ($MILLION)
FIG. 42 MERCK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 43 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 44 GSK: REVENUE, 2013-2015 ($MILLION)
FIG. 45 GSK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 46 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 47 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 48 NOVARTIS: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 49 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 50 ASTRAZENECA: REVENUE, 2013-2015 ($MILLION)
FIG. 51 ASTRAZENECA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 52 ASTRAZENECA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 ROCHE: REVENUE, 2013-2015 ($MILLION)
FIG. 54 ROCHE: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 55 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 56 TEVA: REVENUE, 2013-2015 ($MILLION)
FIG. 57 TEVA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 58 TEVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 59 VECTURA: REVENUE, 2013-2015 ($MILLION)
FIG. 60 PFIZER: REVENUE, 2013-2015 ($MILLION)
FIG. 61 PFIZER: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 62 PFIZER: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 63 ABBOTT: REVENUE, 2013-2015 ($MILLION)
FIG. 64 ABBOTT: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 65 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com